iThriveMD Review: What Its GLP-1 Prices Commit You to—and What Remains Unclear

The most consequential phrase on iThriveMD’s GLP-1 pages may not be the introductory price. It is the statement that packages are paid in full at purchase and automatically renew at the selected interval. Elsewhere, the clinic advertises payment plans, memberships charged every 28 days and packages labeled in months but described in weeks. For an adult comparing treatment options, those details determine more than affordability: they determine what authorization to pay might continue after the first order.

iThriveMD describes itself as a longevity-focused medical clinic addressing weight gain, fatigue, hormonal changes and age-related decline. Its documented weight-management offerings include compounded subcutaneous semaglutide and tirzepatide, clinic-based care and eligible home treatment. This review examines the public documentation consulted October 19, 2026, rather than a purchased service or signed patient agreement. Some pages could not be reloaded during the final refresh, so the earlier documented terms need current confirmation. The central question is whether the clinical service and financial commitment are defined clearly enough before enrollment.

At a glance

Documented medications: iThriveMD offers compounded injectable semaglutide and tirzepatide; its microdosing program is limited to tirzepatide.
Sources: [11]
Introductory monthly offers: Semaglutide is advertised at $199 initially, then $299; tirzepatide at $299 initially, then $399. Monthly plans state billing every 28 days. The $100 promotion applies only to the first month and excludes packages.
Sources: [5] [6] [8]
Renewal obligation: The homepage says packages are paid in full at purchase and automatically renew at the selected package interval, while product pages also advertise payment plans.
Sources: [8] [5] [6]
Geographic access: The clinic advertises telehealth across California and Arizona with the same member pricing; Scottsdale is listed as a telehealth appointment rather than a documented street-address clinic.
Sources: [8] [7]
Unresolved exit terms: The consulted documentation does not establish cancellation deadlines, cancellation charges, refund rights or the procedure for stopping automatic renewal.
Sources: [3] [8]

Start with the renewal authorization, not the advertised discount

iThriveMD’s homepage states: “All packages are paid in full at the time of purchase and automatically renew at the interval associated with the selected package.” That is a material commitment, particularly for someone considering a longer package. Separately, its general notice says all memberships are charged every 28 days from their start date. The documentation does not fully explain how that membership rule interacts with a package renewing after 12, 24 or 48 weeks.

The product pages introduce another unresolved distinction: each longer package advertises a payment plan. That means the published presentation includes a possible payment alternative, not simply one mandatory upfront arrangement. However, it does not identify a financing company, interest rate, approval requirement or installment schedule. Before authorizing payment, ask which arrangement governs your purchase and whether any financing obligation continues if clinical treatment ends.

The monthly medication cards say there is “No long-term commitment.” That is useful, but it does not establish the notice required to avoid another charge. Nor does it explain whether canceling a membership also stops an already submitted pharmacy order. A practical enrollment-terms checklist can help organize these questions, but only the clinic’s applicable written agreement can settle them for this purchase.

Sources: [8] [3] [5] [6]

The first payment and the recurring price are different offers

For compounded subcutaneous semaglutide, the monthly card advertises $199 with $100 off, billing every 28 days, followed by $299 “per month after.” Compounded subcutaneous tirzepatide is advertised at $299 initially and $399 afterward, also billed every 28 days. The homepage limits the $100 discount to the first month and excludes package purchases. Those introductory amounts should not be treated as the ongoing cost or combined with package discounts.

The table preserves the longer-package figures as displayed; these are not independently established total purchase prices. The cards pair those figures with prepaid periods and provider-advertised monthly savings. Semaglutide’s advertised savings are $29.90, $44.85 and $59.80 per month, respectively; tirzepatide’s are $99.75, $139.65 and $199.50. All six cards advertise payment plans and shipment every 28 days. A written checkout quote is needed to establish the full amount collected.

The labels “3-month,” “6-month” and “12-month” correspond to 12, 24 and 48 weeks—not equivalent calendar-month periods. Neither those durations nor shipment frequency establishes the quantity supplied. Tirzepatide’s specific page says its price stays the same regardless of dose, although the broader weight-loss page describes cost as dose-dependent. This makes billing intervals and commitments especially important to confirm for the selected product rather than infer from a headline.

Standard compounded injectable packages: displayed figures are not confirmed package totals
Medication and package label	Displayed price and discount	Published payment and shipment language
Semaglutide, 3-month	$269.10; 10% off	12 weeks paid upfront; ships every 28 days; payment plan available
Semaglutide, 6-month	$254.15; 15% off	24 weeks paid upfront; ships every 28 days; payment plan available
Semaglutide, 12-month	$239.20; 20% off	48 weeks paid upfront; ships every 28 days; payment plan available
Tirzepatide, 3-month	$299.25; 25% off	12 weeks paid upfront; ships every 28 days; payment plan available
Tirzepatide, 6-month	$259.35; 35% off	24 weeks paid upfront; ships every 28 days; payment plan available
Tirzepatide, 12-month	$199.50; 50% off	48 weeks paid upfront; ships every 28 days; payment plan available

Sources: [5] [6] [8] [10]

Microdosing has its own package economics and enrollment language

iThriveMD documents microdosing only for tirzepatide; it separately offers semaglutide maintenance plans for people who have completed a full GLP weight-loss program. The microdosing page lists $585 for 12 prepaid weeks, advertised as $195 per month. Its six-month option is $1,053 for 24 prepaid weeks, with 10% off and an advertised $175.50 monthly equivalent. Both state shipment every 28 days and a payment-plan option.

The twelve-month microdosing package lists $1,755 for 48 prepaid weeks, 25% off and an advertised $146.25 monthly equivalent, again with 28-day shipments and a payment-plan option. The provider advertises monthly savings of $20 on the six-month package and $48.75 on the twelve-month package. The six-month savings claim does not exactly match the difference between its displayed monthly equivalents; it should be treated as provider advertising, not a verified calculation.

This program includes an initial 30-minute consultation and monthly 15-minute follow-ups. Its enrollment language says no particular BMI or laboratory work is required, unlike the homepage’s general statement about baseline testing before any plan. The clinic also describes microdosing as off-label and acknowledges that FDA has not specifically studied or approved those lower doses. Enrollment accessibility and package discounts do not establish clinical suitability, comparative effectiveness or a guarantee of tolerability.

Sources: [11] [4] [8]

Cancellation and refunds remain the largest contract gaps

The consulted Terms of Use material mainly provides navigation and general notices rather than a detailed GLP-1 cancellation policy. It does not establish how to submit cancellation, how much notice is required, whether a fee applies or when an automatic renewal becomes irreversible. This absence is not proof that cancellation is unavailable. It means the public documentation reviewed here is insufficient to describe a dependable exit process.

Refunds are a separate question. Ending future renewals does not establish entitlement to money already paid, and a prepaid package does not itself explain what happens to unused services. Ask for the rules covering clinical ineligibility after payment, stopping because of tolerability, medication already ordered and treatment that cannot continue. The reviewed material does not establish refund amounts, exclusions, processing periods or a guarantee that a refund will be available.

For a longer package, request the renewal date, renewal amount, cancellation method and applicable notice deadline together in writing. Keep confirmation of any request rather than assuming that a conversation during a clinical visit changes billing authorization. Our guide to cancellation notice and renewal dates explains the distinction, but no specific deadline should be imported into iThriveMD’s terms from another provider’s policy.

Sources: [3] [8]

Define the clinical services included in the commitment

The published intake sequence starts with an online questionnaire about health and goals, then a clinical consultation reviewing diagnostic laboratories and a personalized plan. Treatment may begin in clinic or at home if eligible, followed by progress tracking and plan adjustments. The general weight-loss page says each plan includes monthly consultations, metabolic laboratory testing and real-time progress tracking. These are meaningful service descriptions, although they do not resolve every potential separate charge.

The homepage promises in-depth diagnostic testing and baseline laboratories before any plan begins. That broad statement contrasts with microdosing enrollment without laboratory work. Ask whether enrollment and treatment initiation have different requirements, which tests apply to the chosen program and whether repeat testing is included. The documentation also does not establish clinical-review turnaround, appointment availability or support response times, so “ongoing” follow-up should not be read as immediate access.

For standard GLP therapy, iThriveMD says adults with BMI over 27 plus weight-related health conditions, or BMI over 30, may qualify; it offers free eligibility assessments and does not require diabetes. These are the clinic’s general screening statements, not an individual eligibility decision or a complete exclusion list. NIDDK emphasizes that medication selection also requires discussion of health conditions, other medicines, side effects and costs with a clinician.

Sources: [5] [11] [8] [4] [10] [2]

Identify who provides care and where appointments occur

iThriveMD lists Samir Damani, MD, as founder and cardiovascular specialist. It identifies Aubrey Anderson and Thomas Macsay as naturopathic doctors, with Macsay also listed as vice president of clinical operations. Those are provider-published credentials, not independently verified licenses, and the professional roles should not be treated as interchangeable. Before enrollment, establish which clinician conducts the consultation, who prescribes and who handles medication-related concerns between scheduled visits.

A referral disclosure names Vishal Verma, MD, Samir Damani, MD, Empower Aesthetics Medical Group, Inc. and iThriveMD PC. It says the listed doctors have financial interests in, or provide services to, one or more listed doctors or facilities. This disclosure is relevant to understanding the business relationships, but it does not by itself identify the legal entity responsible for every patient’s prescribing, billing or refund decision.

The homepage advertises telehealth across California and Arizona at the same member pricing. Its directory supplies California street addresses in Roseville, Walnut Creek, Sunnyvale and Laguna Niguel; Scottsdale is listed as a telehealth appointment. Do not assume every directory entry is an injection clinic. The consulted documentation also does not confirm Spanish-language care, interpretation, a patient portal or clinical messaging channels, making the actual contact route another useful pre-enrollment question.

Sources: [9] [8] [7]

Pharmacy and shipping responsibilities need a clearer handoff

The tirzepatide page offers delivery to the patient’s door or clinic visits for support and injections. It also promises injection training at the first visit, video tutorials and continuing support. The semaglutide page includes clinical oversight and coaching and says dispensing occurs through a LegitScript-certified facility. The consulted material does not name that facility or establish the identity, address or license of the pharmacy preparing and dispensing the compounded medication.

Shipment every 28 days is a dispatch schedule, not an arrival promise. The documentation does not specify the carrier, shipping charges, transit time, storage instructions or replacement policy for a damaged or temperature-compromised delivery. These omissions matter because a patient needs to know which organization handles an interrupted shipment and who authorizes a replacement. A provider-responsibility map can help separate clinic, prescriber and pharmacy questions before an order is placed.

FDA recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. FDA also recommends compounded drugs only when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Compounded preparations are not FDA approved or subject to FDA premarket review; that alone neither proves clinical inequivalence nor validates the clinic’s quality claims.

Sources: [11] [6] [5] [3] [1]

Separate payment flexibility from coverage and clinical promises

iThriveMD says it does not accept insurance for tirzepatide treatment and allows HSA or FSA funds for payment. For semaglutide, it uses more conditional language: patients may be able to use HSA or FSA funds, and the clinic can supply documentation for potential out-of-network reimbursement. Neither statement guarantees plan reimbursement or establishes an individual account’s payment eligibility. The broader weight-loss offering says no insurance or referral is required.

The clinic also advertises B12 injections, IV therapy, hormone replacement therapy and advanced diagnostic testing. Their presence on a weight-loss page does not establish that all are included in a GLP-1 package. Request an itemized agreement distinguishing the medication, consultation schedule, laboratories, supplies, delivery and any optional services. This is particularly important when the public language combines a medical program, a membership and separately described treatments.

Finally, contract clarity is not evidence of treatment outcomes. iThriveMD’s notice says results have not been independently verified. Its microdosing FAQ acknowledges possible digestive or appetite-related effects despite more reassuring promotional language elsewhere. NIDDK describes follow-up as assessment of response and tolerability, not simply continued payment. A useful agreement should explain how clinical reassessment affects future services and charges without promising that a particular result, prescription or continued treatment will follow.

Sources: [6] [5] [10] [3] [4] [2]

Questions & answers

Does iThriveMD’s $199 semaglutide offer continue after the first payment?

Not according to the published promotion. The monthly semaglutide card shows $199 initially and $299 afterward, with billing every 28 days. The homepage says the $100 discount applies only to the first month and cannot be used for package purchases. Ask for the next charge’s exact date and amount, because the page’s monthly wording should not be interpreted as calendar-month billing.

Sources: [5] [8]

Must I pay an entire longer package upfront?

The homepage says packages are paid in full at purchase, but the medication and microdosing cards also advertise payment plans. The public documentation does not reconcile those statements or disclose financing terms. Ask for the upfront option and any installment alternative separately, including the total obligation, interest or fees, approval requirements and what happens to remaining payments if treatment is discontinued.

Sources: [8] [5] [6] [4]

Can I cancel iThriveMD and receive a refund?

The reviewed documentation does not establish that answer. Monthly cards advertise no long-term commitment, but the applicable cancellation method, notice period and refund boundaries were not documented. Packages automatically renew according to the homepage. Before paying, obtain separate answers about stopping future renewals, canceling a pending pharmacy order and recovering money already paid; none necessarily follows from the others.

Sources: [5] [6] [8] [3]

Are laboratory tests required for iThriveMD microdosing?

The microdosing page says neither a particular BMI nor laboratory work is required to enroll. That differs from the homepage’s statement that baseline laboratories precede any plan. Ask whether testing is unnecessary only for enrollment or also before prescribing, and whether later tests carry separate charges. The microdosing price documents a 30-minute initial consultation and monthly 15-minute follow-ups, not a fully itemized laboratory policy.

Sources: [4] [8]

Can I choose home delivery instead of clinic injections?

The tirzepatide page explicitly offers home shipment or clinic visits for support and injections. The broader intake process says home treatment is available if eligible, so the choice is not documented as unconditional. Confirm the applicable appointment location, supplies, delivery fees and problem-resolution contact. The published every-28-day shipping schedule does not establish arrival time or the quantity in each shipment.

Sources: [6] [5]

Does iThriveMD accept insurance for these medications?

Its tirzepatide page says insurance is not accepted for that treatment and that HSA or FSA funds can be used. Semaglutide documentation says HSA/FSA use may be possible and offers paperwork for potential reimbursement when a plan includes out-of-network benefits. Confirm coverage with the insurer separately; providing reimbursement documentation is not a promise that the plan will pay or that treatment will be covered.

Sources: [6] [5]

Our assessment

iThriveMD documents a substantive clinical offering: two compounded injectable medication options, consultation and follow-up services, California–Arizona telehealth, clinic access and home delivery options. Its pages also disclose introductory prices, longer packages and automatic renewal rather than leaving the entire financial model unpublished. The weakness is how those disclosures fit together. Calendar-month language, 28-day membership billing, week-based packages, upfront-payment language and advertised payment plans do not yet form a fully clear contract. Cancellation, refunds and pharmacy responsibilities remain important gaps. Before committing—especially to a longer package—the useful next step is a written agreement naming the medication, total payment obligation, included services, renewal schedule, cancellation procedure and dispensing pharmacy. Clear answers would improve the purchasing decision; they would not establish clinical suitability or guarantee results.

Visit iThriveMD’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

iThriveMD Review: What Its GLP-1 Prices Commit You to—and What Remains Unclear

At a glance

01Start with the renewal authorization, not the advertised discount

02The first payment and the recurring price are different offers

03Microdosing has its own package economics and enrollment language

04Cancellation and refunds remain the largest contract gaps

05Define the clinical services included in the commitment

06Identify who provides care and where appointments occur

07Pharmacy and shipping responsibilities need a clearer handoff

08Separate payment flexibility from coverage and clinical promises